Client results
Real devices. Real coverage wins.
Fifteen years of engagements across device categories, payer classes, and coverage situations. These are not case studies from a textbook. They are the track record behind the method.
Client engagements
Across device categories and payer classes
Payers covered
Commercial, Medicare, Medicaid, managed care
Coverage success rate
Across all active engagements
Denied claims recovered
Through appeal and reconsideration
NCDs influenced
National Coverage Determinations at CMS
Track record
From FDA clearance to full commercial coverage
Client devices
Six devices across six categories, from pre-market strategy to denied claims recovery.
Nevro Senza HF10
Nevro Corp
Established coverage across 12 commercial payers within 8 months of FDA clearance. Identified and closed 3 Aetna-specific documentation gaps that were driving denials.
Spineology OptiMesh
Spineology
Built the coverage strategy before FDA submission. Identified the evidence gaps that would trigger payer scrutiny and structured the clinical trial to address them. Coverage established at launch.
Curonix Freedom PNS
Curonix
$847K in denied claims recovered through targeted appeal strategy. Identified that denials were driven by a single documentation gap in the PA template, not a coverage policy issue.
Smith+Nephew Tula System
Smith+Nephew
Detected a UnitedHealthcare policy update that would have restricted coverage for the Tula System 6 weeks before it took effect. Submitted clinical evidence package in time to prevent the restriction.
Noctrix Nidra TOMAC
Noctrix Health
New device category with no existing payer coverage framework. Built the clinical evidence strategy and payer engagement plan that established coverage as a new category at 7 payers.
AVITA Medical RECELL
AVITA Medical
PMA-approved device facing inconsistent coverage across commercial payers. Mapped the policy landscape, identified the 4 payers with the highest denial rates, and built targeted evidence packages for each.
The track record
From FDA clearance to full commercial coverage.
Six devices taken from FDA clearance to full commercial coverage. Three NCDs influenced at CMS. $2.4M in denied claims recovered. Forty-seven payers where the method has been applied.
The numbers are the result of a method built by people who have done this work, not a platform that monitors policies and hands you a dashboard.
Every engagement in this track record was won by identifying the specific gaps and levers for a specific device at a specific payer. That is what Polify encodes.
Neuromodulation
Nevro Senza HF10, Curonix Freedom PNS
Spinal Implants
Spineology OptiMesh
Wound Care
Smith+Nephew Tula System
Sleep Therapy
Noctrix Nidra TOMAC
Regenerative Medicine
AVITA Medical RECELL
Your device is next.
Start your intake today.
The same method that built coverage for these devices is available for yours. Begin the intake and see what Polify finds.